Oncology · Gastric CancerTrial Updateclinicalmid-term

Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Astellas Pharma7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 12:30:47 PM

Assessment confidence: 40% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.

Executive Thesis

The initiation of the ASP2138 trial represents a significant opportunity for Astellas Pharma to enhance its oncology portfolio, particularly in the HER2-negative gastric cancer segment. Success in this trial could provide a competitive edge against existing therapies and improve treatment options for a challenging patient population. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 1 ranked evidence items (0 high-relevance).

Strategic Assessment

Success in this trial may enhance Astellas Pharma's oncology portfolio and provide a new therapeutic avenue for a challenging patient population, potentially impacting market share against competitors. The strongest clinical anchor is A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer (ClinicalTrials.gov), entity match (astellas pharma). If successful, ASP2138 could capture market share in a competitive landscape, potentially leading to increased revenue and positioning Astellas Pharma favorably against competitors in the gastric cancer treatment market.

Competitive Pressure

The most relevant competitive pressure comes from This trial could position ASP2138 as a novel treatment option in a competitive landscape dominated by existing therapies for gastric cancer, particularly for patients who are HER2-negative..

Regulatory Outlook

Regulatory risk is concentrated around The trial's outcomes will be critical for future regulatory submissions and could influence labeling and approval pathways for ASP2138 as a novel treatment option..

Key Risks

Elevated medium regulatory exposure for Astellas Pharma could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Signal severity is high — leadership review is warranted.

Key Opportunities

If successful, ASP2138 could capture market share in a competitive landscape, potentially leading to increased revenue and positioning Astellas Pharma favorably against competitors in the gastric cancer treatment market.
Success in this trial may enhance Astellas Pharma's oncology portfolio and provide a new therapeutic avenue for a challenging patient population, potentially impacting market share against competitors.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety, particularly progression-free survival rates compared to placebo, as well as any updates on patient recruitment and interim analyses.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONTRUZANT (SUPPL)
FDAlow relevance
Regulatory pathway relevance (bla)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
ClinicalTrials.govmedium relevance
Entity match (astellas pharma)
FDA document
View source
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

No evidence in this category.

Intramuscular patient-derived xenografts achieve high engraftment rates in gastric cancer: implications for pharmacodynamic testing and genomic biomarker discovery.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FTO-mediated m(6)A demethylation of BCL6 promotes gastric cancer progression by suppressing ferroptosis.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Astellas Pharma
ASP2138
pembrolizumab

Commercial impact

high

If successful, ASP2138 could capture market share in a competitive landscape, potentially leading to increased revenue and positioning Astellas Pharma favorably against competitors in the gastric cancer treatment market.

Regulatory impact

medium

The trial's outcomes will be critical for future regulatory submissions and could influence labeling and approval pathways for ASP2138 as a novel treatment option.

What to watch

Monitor trial results for efficacy and safety, particularly progression-free survival rates compared to placebo, as well as any updates on patient recruitment and interim analyses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.

Signals